When was Aerogen founded?

Aerogen was founded in 1997 and raised its 1st funding round 1 year after it was founded.

Where is Aerogen located?

Aerogen is headquartered in Galway, Ireland. It is registered at 131, Rectangle-1, D-4, District Centre, Saket, New Delhi, New Delhi, Delhi, India, 110017.

Who is the current CEO of Aerogen?

Jane Shaw Carpenter of Aerogen.

How many employees does Aerogen have?

As of Jul 31, 2026, the latest employee count at Aerogen is 713.

Is Aerogen a funded company?

Aerogen is a funded company, having raised a total of $18M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 17, 1998.

When was the latest funding round of Aerogen?

Aerogen's latest funding was a $***** Grant (prize money) round on Jun 01, 2022, with participation from 1 investor.

Where does Aerogen rank among its competitors?

Aerogen ranks 2nd amongst 16 active competitors, of which 5 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Nebu~Flow, which secured $2.69M in Jun, 2026.

Who are the top competitors of Aerogen?

Aerogen's top competitors include Qnovia, Nebu~Flow and Flyp Nebulizer. Among them, Nebu~Flow secured the most recent funding round in June, 2026.

Aerogen - 2026 Company Profile, Team, Funding & Competitors

Q: Is Aerogen an acquired company?

Aerogen got acquired by Nektar on Aug 15, 2005.

Aerogen is an acquired company based in Galway (Ireland), founded in 1997. It operates as a Manufacturer of vibrating mesh nebulizers for aerosol drug delivery. Aerogen has raised $18M in funding. The company has 16 active competitors, including 5 funded and 3 that have exited. Its top competitors include companies like Qnovia, Nebu~Flow and Flyp Nebulizer.

Company Details

Manufacturer of vibrating mesh nebulizers for aerosol drug delivery. These devices facilitate respiratory therapy across various ventilation settings, including invasive and non-invasive mechanical ventilation, high-flow, and self-ventilating therapies. The technology is designed for ease of use and effectiveness. Products include single-patient-use devices and handheld units for use in conjunction with other respiratory equipment. The company also provides controllers and accessories.

Website: aerogen.com
Social
Email ID: *****@aerogen.com
Registered Address: 131, Rectangle-1, D-4, District Centre, Saket, New Delhi, New Delhi, Delhi, India, 110017

Key Metrics

Founded Year

1997

Location

Galway, Ireland

Stage

Acquired

Total Funding

$18M in 4 rounds

Latest Funding Round

Grant (prize money), Jun 01, 2022, $*****

Investors

Western Technology Investment & 11 more

Ranked

2^nd among 16 active competitors

Employee Count

713 as on Jul 31, 2026

Similar Companies

Qnovia & 15 more

Exit Details

Acquired by Nektar (Aug 15, 2005)

View Aerogen's full profile

Aerogen is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AEROGEN MEDICAL DEVICES INDIA PRIVATE LIMITED CIN: U51909HR2019PTC144518 , India, Active	Dec 17, 2019	0 - ₹10 Cr (As on Mar 31, 2025)	-
AEROGEN LTD CIN: 0769.712.618 , Belgium, Active	Jul 01, 2021	-	-	-

Aerogen got acquired by Nektar on Aug 15, 2005 at an acquisition amount of $*****.

Click here to take a look at Aerogen's acquisition in detail

Aerogen has raised a total funding of $18M over 4 rounds. Its first funding round was on Sep 17, 1998. Its latest funding round was a Grant (prize money) round on Jun 01, 2022 for $*****. 1 investor participated in its latest round. Aerogen has 12 institutional investors.

Here is the list of recent funding rounds of Aerogen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2022	1907588	Grant (prize money)	2797489	2204663	2015664	9405491
Jan 01, 2020	1998842	Grant (prize money)	7396540	4089320	9581373	Europa
Jan 02, 2019	2932686	Post IPO	6042402	4394614	7771578	Temasek

Access funding benchmarks and valuations. Sign up today!

View details of Aerogen's funding rounds and investors

Here are the details of Aerogen's key team members:

Jane Shaw Carpenter: CEO of Aerogen.

Aerogen's Board of Directors

Aerogen's board has 3 active members. John Sylvester Power is part of team and Mark Lydon Anthony and Debabrata Bhowmick are independent board members.

Here is the list of Aerogen's board of directors:

Name	Type	Representing	Status	Duration
John Sylvester Power	Team	-	Current	5y 9m
Mark Lydon Anthony	Independent board member	-	Current	1y 8m
zgkqgsq	Independent board member	-	Current	4y 7m

View details of Aerogen's Founder profiles and Board Members

Aerogen's employee count trend

Aerogen has 713 employees as of Jul 26. Here is Aerogen's employee count trend over the years:

Uncover Aerogen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aerogen include Qnovia, Nebu~Flow and Flyp Nebulizer. Here is the list of Top 10 competitors of Aerogen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Qnovia 2018, Richmond (United States), Series B	Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals	$50M	Blue Ledge Capital, Evolution VC Partners ... & 4 others	55/100
2nd	Aerogen 1997, Galway (Ireland), Acquired	Manufacturer of vibrating mesh nebulizers for aerosol drug delivery	$18M	Western Technology Investment, Invesco Mutual Fund ... & 10 others	52/100
3rd	Nebu~Flow 2019, Glasgow (United Kingdom), Series A	Developer of aerosol delivery platform technology	$7.97M	Foresight Group, SCVC & 8 others	51/100
4th	Flyp Nebulizer 2017, Fairfield (United States), Series B	Developer of a portable nebulizer for asthma and COPD	$4M	HighCape Capital, Connecticut Innovations ... & 1 others	37/100
5th	Convexity Scientific 2013, Fairfield (United States), Series A	Developer of medical devices for respiratory diseases	$300K	Connecticut Innovations, emc2fundltd.com & 1 others	36/100
6th	Afrezza 2009, United States, Unfunded	Developer of an inhaled insulin for type 1 and 2 diabetes	-	-	33/100
7th	Medspray 2002, Enschede (Netherlands), Unfunded	Developer of patented aerosol micro‑nozzle spray systems for healthcare	-	-	30/100
8th	Omega Life Science 2011, Migdal HaEmek (Israel), Funding Raised	Developer of a nebulizer	-	Financiere Saint James	28/100
9th	Nebulok 2016, San Sebastian (Spain), Seed	Manufacturer of medical device for nebulized therapies	-	EIT Health, MassChallenge	28/100
10th	HCmed 2014, Taipei (Taiwan), Public	Developer of inhalation device to treat people suffering from respiratory diseases.	-	-	28/100